계명대학교 의학도서관 Repository

Dysport and Botox at a Ratio of 2.5:1 Units in Cervical Dystonia: A Double-blind, Randomized Study

Metadata Downloads
Author(s)
Ji Young YunJae Woo KimHee-Tae KimSun Ju ChungJong-Min KimJin Whan ChoJee-Young LeeHa Neul LeeSooyeoun YouEungseok OhHeejeong JeongYoung Eun KimHan-Joon KimWon Yong LeeBeom S. Jeon
Keimyung Author(s)
You, Soo Yeoun
Department
Dept. of Neurology (신경과학)
Journal Title
Movement Disorders
Issued Date
2015
Volume
30
Issue
2
Keyword
cervical dystoniatorticollisbotulinum toxinmotor controlmovement disorders
Abstract
We aimed to compare Dysport (abobotulinumtoxinA, Ipsen Biopharm, Slough, UK) and Botox (onabotulinumtoxinA, Allergan, Irvine, CA, USA) at a 2.5:1 ratio in the treatment of cervical dystonia (CD). A Dysport/Botox ratio of lower than 3:1 was suggested as a more appropriate conversion ratio, considering its higher efficacy and more frequent incidence of adverse effects not only in the treatment of CD but also in other focal movement disorders. A randomized, double-blind, multicenter, non-inferiority, two-period crossover study was done in CD, with a duration of at least 18 months. Patients were randomly assigned to treatment for the first period with Dysport or Botox, and they were followed up for 16 weeks after the injection. After a 4-week washout period, they were switched to the other formulation and then followed up for 16 weeks. The primary outcome was the changes in the Tsui scale between the baseline value and that at 1 month after each injection. A total of 103 patients were enrolled, and 94 completed the study. Mean changes in the Tsui scale between baseline and 4 weeks after each injection tended to favor Botox; however, this was not statistically significant (4.0 ± 3.9 points for the Dysport treatment vs. 4.8 ± 4.1 points for Botox; 95% confidence interval, −0.1-1.7; P = 0.091). The mean change of the Toronto western spasmodic torticollis rating scale score, the proportion of improvement in clinical global impression and patient global impression, and the incidences of adverse events were not significantly different between the two treatments. With regard to safety and efficacy, Dysport was not inferior to Botox in patients with CD at a conversion factor of 2.5:1. [http//clinicaltrial.gov: NCT00950664] © The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Keywords: cervical dystonia, torticollis, botulinum toxin, motor control, movement disorders
Keimyung Author(s)(Kor)
유수연
Publisher
School of Medicine
Citation
Ji Young Yun et al. (2015). Dysport and Botox at a Ratio of 2.5:1 Units in Cervical Dystonia: A Double-blind, Randomized Study. Movement Disorders, 30(2), 206–213. doi: 10.1002%2Fmds.26085
Type
Article
ISSN
0885-3185
DOI
10.1002%2Fmds.26085
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/33464
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Neurology (신경과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.